DCAT Value Chain Insights

The Pharma Pulse: Re-shoring Drug Manufacturing

Reshoring manufacturing, including drug manufacturing, has gained policy momentum in the US and EU stemming in part from supply-chain vulnerabilities exposed during the COVID-19 pandemic. But will...

Generics and the EU: The Push for Value-Added Medicines

Medicines for Europe, which represents generic-drug and biosimilar manufacturers, is calling on the EU to recognize value-added medicines as a separate group of medicines and with that recognition,...

SPONSORED CONTENT

Supply Chain Security -- If Your API Supply Is Important, You Should Take Five Minutes To Read This

Information
February 24, 2021
Sponsored by ChemWerth

We all know that active pharmaceutical ingredient (API) end user supply chain security is a critical component to getting the finished dosage to market. Securing the supply chain means that...

Read More
Embarking Upon the Commercial Manufacturing Journey for a Biologic: Strategies to Achieve Successful Approval & Launch

Information
February 10, 2021
Sponsored by Catalent Biologics

In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon...

Read More
Build or Buy Challenge: Six Advantages of Using a Pre-Qualified, Fully Customizable GMP Environment

Information
January 27, 2021
Sponsored by Almac

Today, biopharma companies face growing challenges when capacity is at a premium. Investment decisions must be made to ultimately determine the expansion of facilities, headcounts and technology...

Read More